OncoAlert

@OncoAlert

🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are 🚨

Worldwide
Vrijeme pridruživanja: ožujak 2019.

Tweetovi

Blokirali ste korisnika/cu @OncoAlert

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncoAlert

  1. Prikvačeni tweet
    10. sij

    OncoAlert 360🚨is a network of oncology professionals w/1 mission: Fight cancer through social media by disseminating potentially Practice Changing knowledge( Oncology 360 degrees)YOU are 🚨

    Poništi
  2. proslijedio/la je Tweet
    prije 1 sat

    MONALEESA3 update: —> Ribociclib prolongs OS when added to Fulvestrant in postmenopausal women with HR+ mBC (58% vs 46% alive at 42 mo, HR 0.72, p 0.004) Of note, pts reviving fulv+ribo as 1st line achieved a mPFS OF 33 months!

    Poništi
  3. proslijedio/la je Tweet

    PD-1 Resistance Taskforce created definitions for primary resistance & 2ndary resistance. (Caveats: e.g. should not be applied to pts who discontinued early due to irAEs!). These criteria are CRITICAL as we increasingly study PD-1 resistance!

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    prije 7 sati

    🇪🇸 Effectiveness of sacubitril–valsartan in cancer 👥 with heart failure➡️ 📌SAC/VAL ⏏️echocardiographic functional and structural parameters, 📌⬇️NT-proBNP levels 📌✅symptomatic status in this special oncologic population ⚠️ also well tolerated in these patients

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  5. proslijedio/la je Tweet
    prije 3 sata

    We are already at Symposium, with the expert Robert Dreider, member of the Scientific Committee

    Poništi
  6. proslijedio/la je Tweet
    prije 2 sata

    –PD-(L)1 More than 100 clinical trials of neoadjuvant anti–PD-(L)1 therapy are currently ongoing, both as monotherapy and in combinations with other immunotherapies, radiation therapy, chemotherapy

    Poništi
  7. proslijedio/la je Tweet

    NEW Review by Ton N Schumacher et al, on cell states that have been identified in human tumours using , the potential roles they play in tumour control as well as how they are influenced by .

    CD8+ T cell states in human cancer: insights from single-cell analysis
    Poništi
  8. proslijedio/la je Tweet

    Thrilled to see our review on Sarcomatoid/Rhabdoid RCC for published! With mentor extraordinaire . Exciting new data are emerging for this aggressive disease and our review tries to summarize it all.

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    prije 5 sati

    I will never ever stop repeating how important is having a good work-life balance to my colleagues and to trainees

    Poništi
  10. proslijedio/la je Tweet
    prije 3 sata

    a smart idea of smart young oncologists on oncotwitting!

    Poništi
  11. proslijedio/la je Tweet
    prije 4 sata

    PIK3CA-mutated Metastatic : Analysis from SAFIR02 trial results in better understanding of characteristics of MBC population harbouring PIK3CA mutations

    Poništi
  12. proslijedio/la je Tweet
    prije 6 sati

    ESMO members: last few days to book your accommodation for 😀 From 10 February, the hotel booking tool will be open to all Congress participants – make the most of this member-only access now to reserve.

    Poništi
  13. proslijedio/la je Tweet
    prije 8 sati

    Editorial: The return on investment of cancer-genome sequencing projects will come when that information can be used to tailor therapy to individual patients. And for that to be achieved, clinical background information on study participants is essential.

    Poništi
  14. proslijedio/la je Tweet

    Study with et al quantified commercial tweeting (big pharma & biotech) at a major international conference (). We excluded these tweets to study content of scientific & clinical interest.

    Poništi
  15. proslijedio/la je Tweet
    prije 8 sati
    Poništi
  16. proslijedio/la je Tweet

    Next at Dr. Luis Ruffolo (great to see a surgical resident on the podium!): semaphorin 4D to sensitize pancreatic cancer to checkpoint blockade. Don't want to post his unpublished data- summary: combinations with SEMA4Di+ICI increases TIL and decrease tumor growth.

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    prije 3 sata

    Proud to announce with co-chair the 2nd Annual Kidney Cancer Research Summit, , a meeting focused on translational science in RCC fueled by the KCRP grant funding. LINK TO REGISTER/More: please Re-tweet!

    , , i još njih 5
    Poništi
  18. proslijedio/la je Tweet
    prije 3 sata

    Really important topic for tonight's - stigma and nihilism - join if you can

    Poništi
  19. proslijedio/la je Tweet
    prije 4 sata

    Interesting paper on a hot topic. Kudos to all the authors

    Poništi
  20. proslijedio/la je Tweet
    prije 4 sata

    Experiences of BRCA1/2 Gene Mutation–Positive Women With Can... : Cancer Nursing - congratulations to ⁦

    Poništi
  21. proslijedio/la je Tweet
    prije 3 sata

    🧠Very interesting GBM study in Maximal safe resection of contrast-enhancing AND non-enhancing associated w/ longer survival in patients <65 yrs -IDH mutant & wild type -IDH wild type +/- MGMT methylated Link:

    , , i još njih 2
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·